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BACKGROUND: Our previous results showed that nitric
oxide (NO) and bradykinin (BK) mediate the arthritis
induced by Bothrops  jararaca venom  (BjV) in  rab-
bits. In this study, we investigated the contribution of
each receptor of BK as well as the inter-relationship
between  NO  and  eicosanoids  in  BjV-induced
arthritis.
Methods:  The  arthritis  was  induced  in  rabbits  with
16 mg of BjV injected intra-articularly. Prostaglandin
E2 (PGE2),  thromboxane  B2 (TxB2),  leukotriene  B4
(LTB4)  (radioimmunoassay)  and  nitrite/nitrate  con-
centrations  (NO2/NO3)  (Griess  reaction)  were  eval-
uated in the synovial fluid 4 h later. The animals were
prior  treated  with  NO  synthase  inhibitor  (L-NAME;
20 mg/kg/day for  14  days), the B2 antagonist of BK
(HOE-140)  and  the  B1  antagonist  of  BK  (des-
Arg9[Leu8]-bradykinin), both  at  a  dose  of 0.3 mg/kg,
30 min prior to the venom injection.
Results: Data show that L-NAME and HOE-140 treat-
ment were equally able to reduce PGE2 and NO2/NO3
levels without interfering with TxB2 and LTB4 produc-
tion.  On  the  contrary,  the  B1  antagonist  of  BK
inhibited TxB2 and LTB4 production, and did not alter
PGE2 and  NO  metabolites  levels  in  the  inflamed
joint.
Discussions:  The  results  presented  clarify  the  con-
tribution of the kinin system, mainly through the B2
receptor, to the local inflammatory response induced
by BjV, as well as its positive interaction with PGE2
and NO production.
Key  words:  Bothrops  jararaca venom,  Inflammatory
reaction, Arthritis, Bradykinin, Nitric oxide, Eicosanoids
Introduction
Endogenous nitric oxide (NO) has been described as
a  pro-inflammatory  molecule  showing  interactions
with cytokines1–3 and inflammatory products of the
cyclooxygenase pathway.4–10 Studies have shown that
NO increases interleukin-1b and eicosanoid products,
which  may  result  in  an  exacerbated  inflammatory
response.2,3In addition, inhibition of NO biosynthesis
by an L-arginine antagonist reduced prostaglandin E2
(PGE2) production in different models of inflamma-
tory reactions in vivo.11–13
Additionally,  bradykinin  (BK)  and  NO  have been
implicated on eicosanoids and cytokine secretions in
several  experimental  inflammatory  proces-
ses.8,12,13–15 BK acts on the acid arachidonic metabo-
lism via both phospholipase A2
16 and phospholipase
C17 activation. Also, BK is known to release NO from
various  cells,  including  polymorphonuclear18 and
endothelial cells at the site of injury.19
The  acute  inflammatory  reaction  induced  by
Bothrops  jararaca venom  (BjV)  is  determined  by
oedema and leukocyte influx.20–22 These effects are
mediated by histamine, serotonine, products of ara-
chidonic  acid  metabolism,  platelet-activating  factor
and  factors  derived  from  complement  system.20–22
The eicosanoids contribution is relevant to oedema
formation  and  leukocyte  recruitment  during  BjV-
induced  pleurisy  and  air-pouch  inflammatory  reac-
tion.21,22 Recently, to determine the participation of
kinins  and  NO  in  the  local  inflammatory  reaction
induced by BjV, we developed an experimental model
of  arthritis  by  injecting  the  venom  intra-articularly.
The findings that B2 BK antagonist (HOE-140) and NO
synthase  inhibitor  (L-NAME)  treatment  greatly
reduced the cellular influx and protein leakage in the
arthritis induced by BjV clearly implicate kinins and
NO in this phenomenon.23
Since  eicosanoids,  BK  and  NO  are  important
mediators  involved  in  the  inflammatory  reaction
evoked  by  BjV,  and  since  there  is  strong  evidence
regarding the interaction between these mediators on
different models of the inflammatory process, the aim
of this study was to evaluate the participation of each
receptor of BK in NO and eicosanoid production in
the acute inflammatory response evoked by BjV.
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Induction of arthritis
The Animal  Ethics  Committee  of  COBEA  (Brazilian
College of Experimental Animals) approved all experi-
mental procedures, performed on animals in accord-
ance with procedures set by The Universities Federa-
tion for Animals Welfare. The arthritis was induced in
the  knee  joint  of  Male  New  Zealand White  rabbits
(2kg)  by  the  injection  of  BjV  provided  by  the
Laboratory of Herpetology, Butantan Institute, Brazil
(16mg  diluted in  0.5ml  of  saline). The venom was
filtered in sterilising membrane (ester cellulose filter,
0.22mm pore size; Millipore, S Æ ao Paolo, Brazil) before
joint injection. The  contralateral joint  was  injected
with the same amount of bovine serum albumin (BSA)
(Sigma, St Louis, MO, USA). The amount of protein
present in BjV or BSA solution was spectrophotomet-
rically assessed and the equivalent protein concentra-
tion was injected in each joint. Four hours after intra-
articular challenge, the animal was anaesthetised with
a  mixture  of  xylazine  (5mg/kg;  Bayer,  S Æ ao  Paolo,
Brazil)  associated  with  ketamine  (50mg/kg;  Parke
Davis,  S Æ ao Paolo, Brazil)  by  intramuscular  injection
and killed by intravenous injection of 2.0ml of 20%
KCl solution. Immediately after the sacrifice, 2ml of
saline  containing  ethylenediamine  tetraacetic  acid
(1mg/ml) was injected into the knee joint. Synovial
fluid  was  aspirated, the  joint  was  opened and  the
remainder of  the  synovial  fluid  was  recovered and
stored at –70°C.
Pharmacological treatments
A  group  of  animals  were  randomly  treated  with
L-NAME (Sigma), 20mg/kg/day mixed with drinking
water, administered for 2 weeks prior to the induction
of arthritis. Treatments with 0.3mg/kg of B1 or B2 BK
antagonists  des-Arg9[Leu8]-bradykinin  (Sigma)  and
HOE-140 (Hoechst, Frankfurt, Germany), respectively,
were  performed  subcutaneously,  30min  before  the
venom injection. Control animals received an equiva-
lent volume of sterile saline by the same route.
Determination of total NO2·/NO3· levels in the
synovial fluid
The concentration of the total amount of nitrate and
nitrite  (NO2·/NO3·)  anions  (stable  NO  breakdown
products  in  vivo)  present  in  the  synovial  fluid
samples  collected  4h  after  venom  injection  was
determined by Griess reaction. The absorbance was
monitored at 546nm.
Determination of eicosanoids in the synovial
fluid
PGE2, thromboxane B2 (TxB2), leukotriene B4 (LTB4)
levels were assayed in the synovial fluid collected 4h
after venom injection using commercial kits (NEN Life
Science  products,  Boston,  MA,  USA)  as  previously
described.24,25 The competitive binding  radioimmu-
noassays  were  performed  in  polypropylene  tubes
with the reagents diluted in phosphate-buffered saline
(pH 6.8) with gelatine and thimerosal. One hundred
microlitres  each  of  unknown  samples,  of  tracers
(125I-PGE2 and  125I-TxB2 or  3H-LTB4),  and  of  rabbit
antiserum  to each eicosanoids were combined and
incubated overnight at 8°C for  LTB4 determination,
and were then incubated for 2h at 25°C in a water
bath  for  PGE2 and TxB2 determinations.  Unbound
radiolabelled  PGE2 and TxB2 was  removed  by  the
addition of 250ml of donkey anti-rabbit serum coated
onto magnetisable polymer particles, and LTB4 was
removed  by  the  addition  of  250ml  of  2%  charcoal
suspension coated with 0.4%  dextran to the tubes.
After centrifugation, the residual bound activity was
measured  in  each  tube  by  counting  125I-PGE2 and
125I-TxB2 in a g-scintillation counter, and 3H-LTB4 in a
b-scintillation counter. Cross-reactivities of the antise-
rum with other eicosanoids were below 0.05%. The
assay sensitivities were 1.25–160pg/tube (PGE2), and
1.6–200pg/tube (LTB4).
Statistics
Results  are expressed  as  mean  ±  standard error of
mean. Results were analysed by Student’s t-test or by
repeated-measures analysis of variance. When appro-
priate, the data were analysed by the Newman-Keuls
test. The chosen level of significance was 0.05.
Results
Eicosanoids and NO2·/NO3 levels in the
synovial fluid
The synovial fluid collected from animals pre-treated
with  L-NAME,  HOE-140  and  des-Arg9[Leu8]-bradyki-
nin  and  intra-articularly  injected  with  venom,  and
that  from  respective  controls,  was  extracted  to
PGE2,  LTB4 and  TxB2.  The  determinations  were
performed by radioimmunoassay. NO2·/NO3 levels in
diluted  joint wash  were  also  determined by  Griess
reaction. Figure 1A shows the PGE2 level measured
in the synovial fluid obtained 4h after the BjV. Prior
treatment of the rabbits with L-NAME or B2 antago-
nist  of  BK  HOE-140  significantly  reduced  it  when
compared  with  values  obtained  in  samples  from
animals,  which  did  not  receive  pharmacological
treatments.  It  is  important  to  note  that  des-
Arg9l[eu8]-bradykinin  treatment  did  not  interfere
with the production of PGE2. On the contrary, levels
of LTB4 and TxB2 (represented in Fig. 1B and Fig. 1C,
respectively) exhibited a different  pattern of altera-
tion.  They  were  not  altered  after  treatment  with
L-NAME or HOE-140, but they were greatly reduced
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Arg9[Leu8]-bradykinin. Also, values observed in sam-
ples  from  B1  antagonist-treated  animals  were  sig-
nificantly lower than that obtained in samples from
control animals. At  the fourth  hour after  the  injec-
tion  of  BSA,  the  contralateral  joint  exhibited  low
levels of the eicosanoids, similar to the observed in
the saline-injected joint (data not shown).12,26
Similar to the observed pattern of  alteration pro-
moted  in  PGE2 production,  the  level  of  the  total
amount of the NO metabolites (NO2·/NO3·; Fig. 1D)
was  significantly  reduced  in  the  synovial  fluid  col-
lected  from  L-NAME-treated  and  HOE-140-treated
animals when compared with the level observed in
control animals. Differently, the treatment with the B1
antagonist of BK, des-Arg9[Leu8]-bradykinin, did not
affect NO production in  the joint, which exhibited
values of NO2·/NO3 obtained 4h after BjV injection
equivalent to those found in control animals.
Discussion
The data presented in this paper regarding BjV local
effects  corroborate the  positive  cross-talk  between
BK, NO and the cyclooxygenase (COX) product PGE2
described in  the inflammatory reaction induced by
other different agents,8,12,13and additionally show the
main participation of the B2 BK receptor in this axis.
This  last  observation  is  in  accordance with  recent
experimental studies in rats that demonstrated HOE-
140 treatment reduced the oedema induced by local
injection of Bothrops lanceolatus snake venom and
abolished the hyperalgesic effect of BjV.27,28Addition-
ally, the employment of specific receptor antagonists
and enzymatic inhibitors in experimental studies has
demonstrated the participation of BK receptors and
COX  metabolites  on  the  inflammatory  process
evoked by BjV through measurement of its sympto-
matic  effects  such  as  oedema,20,21,29 leukocyte
recruitment21,22,29 and pain.28 However, in the exper-
imental model employed in this study, it was possible
to establish the link between each mediator involved
in  the kinin/NO/COX  axis at the inflammatory site
after pharmacological treatments.
We have clearly demonstrated the contribution of
the  kinin  system,  via  the  B2  receptor,  on  NO
production,  with  subsequent  stimulation  of  PGE2
secretion.  Also,  our  results  showed  that  the  B2
receptor and NO do not participate in LTB4 and TXB2
secretions, which were affected by inhibition of the
B1 receptor. These conclusions are demonstrated by
the following observations: (1) HOE-140 and L-NAME
treatments equally abolished the inflammatory reac-
tion,23 PGE2 and NO2/NO3 levels without interfering
with LTB4 or TxB2 production; and (2) alternatively,
des-Arg9[Leu8]-bradykinin treatment did not alter the
PGE2 and NO metabolites, and greatly reduced LTB4
and TxB2 secretions. It is important to note that our
previous results showed that the NO synthase inhib-
itor (L-NAME) and the B2 receptor antagonist of BK
(HOE-140) treatments promoted a great reduction of
the leukocyte influx (90% of the control animals) to
the articular cavity.23 These data associated with the
Mediators involved in arthritis induced by B. jararaca venom
Mediators of Inflammation · Vol 11 · 2002 15
FIG.  1.  Effects  of  L-NAME,  HOE-140  and  des-Arg
9[leu
8]-
bradykinin treatments on local eicosanoid and NO produc-
tion 4h after intra-articular injection of BjV. (A) PGE2 levels,
(B)  LTB4 levels  (C)  TxB2 levels  and  (D)  NO2·/NO3·  levels
following treatments with L-NAME (n = 5), HOE-140 (n = 4)
and  des-Arg
9[Leu
8]-bradykinin  (n =  5).  Open  column,  the
level of the eicosanoid in control animals (n = 6). Dotted line,
the values of each eicosanoid in the BSA-injected joint. Each
column expresses data as the mean (±s.e.m.). *p < 0.05 by
comparison with control animals.verified low levels of LTB4 in the joint, suggest the
participation  of  other(s)  chemoattractant(s)  in  this
phase of BjV inflammatory reaction. Recent experi-
mental  studies  have  demonstrated  that  Bothrops
snake venoms activate the complement system, with
a  consequent  contribution  of  its  metabolites  on
leukocyte recruitment.22,30 The participation of  the
complement system, BK and NO has been described
in several models of inflammation.31,32The possibility
that the complement system participates in or may be
affected by BK/NO cascade in the bothropic enveno-
mation will be further investigated. In addition, the
treatment  with  the  B1  receptor  antagonist  of  BK,
which promoted reduction of LTB4, was less effective
than  HOE-140,  promoting  40%  of  reduction in  the
cellular  influx  to  the  inflamed  area  (data  not
shown).
In  conclusion,  our  results  suggest  that  the  NO
generation  in  arthritis induced  by  BjV  is  produced
mainly  after  BK  stimulation  through  B2  receptors.
Also, the endogenous release of NO enhances COX
activity  with  further  increase  of  PGE2 production,
demonstrating the inter-relation between the kinins
system with NO and PGE2 in the BjV inflammatory
process.
This paper, together our previous results,23 would
be  useful  to pharmacological interventions to mod-
ulate the imminent inflammatory response evoked by
BjV, which is not neutralised by specific antivenom.
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